March 6 (Reuters) - Ion Investments, which is controlled by
Temasek Holdings of Singapore, is selling part of its stake in
South Korean pharmaceutical company Celltrion 068270.KS and
distributor Celltrion Healthcare 091990.KQ , IFR reported on
Tuesday, citing a term sheet.
In a block deal worth up to 1.1 trillion won ($1.03
billion), Ion plans to sell up to 2,240,000 shares in Celltrion
for 336,700 to 347,800 won each and up to 2,290,000 shares in
Celltrion Healthcare for 108,654 to 112,236 won each, IFR said.
The pricing represents a discount of 6 to 9 percent to their
pre-deal close, said IFR, a Thomson Reuters publication.
($1 = 1,066.5600 won)
(Reporting by Anuradha Subramanyan of IFR; writing by Dahee Kim
in Seoul)
((Dahee.Kim@thomsonreuters.com; +82 2 3704 5643; Reuters
Messaging: dahee.kim@thomsonreuters.com))